Grants per year
Personal profile
Research Interests
I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.
Training Experience
| 2011 | Residency, Case Western Reserve University Hospital |
| 2014 | Fellowship, New York University Medical Center |
Expertise related to UN Sustainable Devlopment Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Michigan State University
… → 2008
MS, Michigan State University
… → 2003
Research interests
- Cancer of Unknown Primary
- Clinical Research
- Drug Discovery
- Melanoma
- Skin Cancer
Fingerprint
Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #OMS-I103: The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressin
Precision Oncology, LLC, OncoSec Medical Incorporated
7/1/20 → 7/1/23
Project: Research project
-
Prot #R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)
ICON Clinical Research Limited, Regeneron Pharmaceuticals, Inc.
2/25/20 → 2/25/23
Project: Research project
-
Prot #R2810-ONC-1806: Cemiplimab Survivorship Epidemiology (CASE) Study
inVentiv Health Clinical, Regeneron Pharmaceuticals, Inc.
12/5/19 → 12/5/22
Project: Research project
-
A multicenter characterization of hepatitis associated with immune checkpoint inhibitors
Patrinely, J. R., McGuigan, B., Chandra, S., Fenton, S. E., Chowdhary, A., Kennedy, L. B., Mooradian, M. J., Palmeri, M., Portal, D., Horst, S. N., Scoville, E. A., Long, G. V., Shi, C., Mehnert, J. M., Sullivan, R. J., Salama, A. K., Sosman, J. A., Menzies, A. M. & Johnson, D. B., 2021, In: OncoImmunology. 10, 1, 1875639.Research output: Contribution to journal › Article › peer-review
Open Access -
Harnessing natural killer cells in cancer immunotherapy: A review of mechanisms and novel therapies
St-Pierre, F., Bhatia, S. & Chandra, S., Apr 2 2021, In: Cancers. 13, 8, 1988.Research output: Contribution to journal › Review article › peer-review
Open Access2 Scopus citations -
The state of Melanoma: Emergent challenges and opportunities
Melanoma Research Foundation, May 2021, In: Clinical Cancer Research. 27, 10, p. 2678-2697 20 p.Research output: Contribution to journal › Article › peer-review
-
A phase ii study of glembatumumab vedotin for metastatic uveal melanoma
Hasanov, M., Rioth, M. J., Kendra, K., Hernandez-Aya, L., Joseph, R. W., Williamson, S., Chandra, S., Shirai, K., Turner, C. D., Lewis, K., Crowley, E., Moscow, J., Carter, B. & Patel, S., Aug 2020, In: Cancers. 12, 8, p. 1-12 12 p., 2270.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
Migden, M. R., Chandra, S., Rabinowits, G., Chen, C. I., Desai, J., Seluzhytsky, A., Sasane, M., Campanelli, B., Chen, Z., Freeman, M. L., Ibrahim, S. F., Khushalani, N. I., Andria, M. & Ruiz, E., 2020, In: Future Oncology. 16, 4, p. 11-19 9 p.Research output: Contribution to journal › Article › peer-review
Open Access6 Scopus citations